Company Overview and News


Add PVA
to your dashboard

Headline News

BRIEF-HSS And PSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data

2017-12-14 reuters
* PSIVIDA CORP - BASED ON STUDY FINDINGS, IMPLANT WAS WELL TOLERATED AND SHOWED POTENTIAL ANALGESIC EFFECTS THROUGH SIX-MONTH STUDY PERIOD Source text for Eikon: Further company coverage: (45-2)

BRIEF-Psivida out-licenses EMEA rights for Durasert three-year treatment for posterior segment Uveitis

2017-07-10 reuters
* Psivida out-licenses emea rights for durasert™ three-year treatment for posterior segment uveitis while retaining u.s. Commercial rights; amended global collaboration agreement with alimera for iluvien® improves psivida’s revenue generation

pSivida's Eye Drug/Device Hits Goals in Second Late-Stage Study

2017-06-13 biospace
Highly Significant Difference Observed Between Durasert and Control Group in Primary Efficacy Analysis of Prevention of Uveitis Recurrence

pSivida's Eye Drug/Device Hits Goals in Second Late-Stage Study

2017-06-13 devicespace
Highly Significant Difference Observed Between Durasert and Control Group in Primary Efficacy Analysis of Prevention of Uveitis Recurrence

pSivida Release; Durasert Three-Year Treatment For Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months

2017-05-08 devicespace
pSivida Anticipates Reporting Top Line Results from the Second Pivotal Phase 3 Clinical Trial in June 2017

pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th

2017-04-20 finance.yahoo
WATERTOWN, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the third quarter of fiscal year 2017 will be released after the market close on Thursday, May 4, 2017, followed the same day by a conference call and live webcast scheduled for 4:30 p.

pSivida Corp. appoints Nancy Lurker chief executive officer

2016-09-16 proactiveinvestors.com.au
pSivida Corp. (ASX:PVA, NASDAQ:PSDV) has appointed Nancy Lurker as its president and chief executive officer and a member of the board of directors. U.S. based pSivida Corp is a dual listed leader in the development of sustained release drug delivery products primarily for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. From 2008 to 2015, Lurker served as chief executive officer and a director of PDI, Inc.

pSivida Corp. achieves efficacy in uveitis trials with unique device

2016-08-10 proactiveinvestors.com.au
pSivida Corp. (ASX:PVA, NASDAQ:PSDV) has met the primary endpoint in utilization study of its new, proprietary 27-gauge inserter ‘Medidur’ for posterior uveitis, an inflammatory disease affecting the eye. Medidur is a miniaturised, injectable, sustained-release drug delivery system designed to treat posterior uveitis. In the study, 66% of injections using the new 27-gauge inserter achieved a satisfactory rating of “Routine,” “Easy” or “Very Easy” while only 46% of injections utilizing the earlier, larger 25-gauge inserter used in the first Medidur Phase 3 trial met that standard.

Appendix 3B

2016-05-05 asx.com.au

Appendix 3B

2016-04-06 asx.com.au